調査レポート | • レポートコード：GIR-2104Z04221 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥494,160 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥741,240 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥988,320 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、樹状細胞がんワクチンのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。樹状細胞がんワクチンの種類別市場規模（クレアバクス、シプリューセル-T（ プロベンジ）、その他）、用途別市場規模（小児科、成人）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・樹状細胞がんワクチンの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：3M Company、Activarti、Argos Therapeutics、Batavia Bioservices、Bellicum Pharmaceuticals、Creagene、DanDrit Biotech、DCPrime、Sanpower Corporation、Elios Therapeutics、ImmunoCellular Therapeutics、Immunicum、Kiromic、Medigene、Merck、Northwest Biotherapeutics、Glaxo Smith Kline、Tellaorporation、Vaxil BioTherapeutics ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：クレアバクス、シプリューセル-T（ プロベンジ）、その他 ・用途別分析2016年-2026年：小児科、成人 ・樹状細胞がんワクチンの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・樹状細胞がんワクチンのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・樹状細胞がんワクチンのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・樹状細胞がんワクチンの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・樹状細胞がんワクチンの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Dendritic Cell Cancer Vaccines market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Dendritic Cell Cancer Vaccines size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Dendritic Cell Cancer Vaccines market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Dendritic Cell Cancer Vaccines market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
CreaVax
Sipuleucel-T (Provenge)
Others
Market segment by Application, can be divided into
Pediatrics
Adults
Market segment by players, this report covers
3M Company
Activarti
Argos Therapeutics
Batavia Bioservices
Bellicum Pharmaceuticals
Creagene
DanDrit Biotech
DCPrime
Sanpower Corporation
Elios Therapeutics
ImmunoCellular Therapeutics
Immunicum
Kiromic
Medigene
Merck
Northwest Biotherapeutics
Glaxo Smith Kline
Tellaorporation
Vaxil BioTherapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Dendritic Cell Cancer Vaccines
1.2 Classification of Dendritic Cell Cancer Vaccines by Type
1.2.1 Overview: Global Dendritic Cell Cancer Vaccines Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Dendritic Cell Cancer Vaccines Revenue Market Share by Type in 2020
1.2.3 CreaVax
1.2.4 Sipuleucel-T (Provenge)
1.2.5 Others
1.3 Global Dendritic Cell Cancer Vaccines Market by Application
1.3.1 Overview: Global Dendritic Cell Cancer Vaccines Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Pediatrics
1.3.3 Adults
1.4 Global Dendritic Cell Cancer Vaccines Market Size & Forecast
1.5 Global Dendritic Cell Cancer Vaccines Market Size and Forecast by Region
1.5.1 Global Dendritic Cell Cancer Vaccines Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Dendritic Cell Cancer Vaccines Market Size by Region, (2016-2021)
1.5.3 North America Dendritic Cell Cancer Vaccines Market Size and Prospect (2016-2026)
1.5.4 Europe Dendritic Cell Cancer Vaccines Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Dendritic Cell Cancer Vaccines Market Size and Prospect (2016-2026)
1.5.6 South America Dendritic Cell Cancer Vaccines Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Dendritic Cell Cancer Vaccines Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Dendritic Cell Cancer Vaccines Market Drivers
1.6.2 Dendritic Cell Cancer Vaccines Market Restraints
1.6.3 Dendritic Cell Cancer Vaccines Trends Analysis
2 Company Profiles
2.1 3M Company
2.1.1 3M Company Details
2.1.2 3M Company Major Business
2.1.3 3M Company Dendritic Cell Cancer Vaccines Product and Solutions
2.1.4 3M Company Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 3M Company Recent Developments and Future Plans
2.2 Activarti
2.2.1 Activarti Details
2.2.2 Activarti Major Business
2.2.3 Activarti Dendritic Cell Cancer Vaccines Product and Solutions
2.2.4 Activarti Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Activarti Recent Developments and Future Plans
2.3 Argos Therapeutics
2.3.1 Argos Therapeutics Details
2.3.2 Argos Therapeutics Major Business
2.3.3 Argos Therapeutics Dendritic Cell Cancer Vaccines Product and Solutions
2.3.4 Argos Therapeutics Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Argos Therapeutics Recent Developments and Future Plans
2.4 Batavia Bioservices
2.4.1 Batavia Bioservices Details
2.4.2 Batavia Bioservices Major Business
2.4.3 Batavia Bioservices Dendritic Cell Cancer Vaccines Product and Solutions
2.4.4 Batavia Bioservices Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Batavia Bioservices Recent Developments and Future Plans
2.5 Bellicum Pharmaceuticals
2.5.1 Bellicum Pharmaceuticals Details
2.5.2 Bellicum Pharmaceuticals Major Business
2.5.3 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccines Product and Solutions
2.5.4 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Bellicum Pharmaceuticals Recent Developments and Future Plans
2.6 Creagene
2.6.1 Creagene Details
2.6.2 Creagene Major Business
2.6.3 Creagene Dendritic Cell Cancer Vaccines Product and Solutions
2.6.4 Creagene Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Creagene Recent Developments and Future Plans
2.7 DanDrit Biotech
2.7.1 DanDrit Biotech Details
2.7.2 DanDrit Biotech Major Business
2.7.3 DanDrit Biotech Dendritic Cell Cancer Vaccines Product and Solutions
2.7.4 DanDrit Biotech Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 DanDrit Biotech Recent Developments and Future Plans
2.8 DCPrime
2.8.1 DCPrime Details
2.8.2 DCPrime Major Business
2.8.3 DCPrime Dendritic Cell Cancer Vaccines Product and Solutions
2.8.4 DCPrime Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 DCPrime Recent Developments and Future Plans
2.9 Sanpower Corporation
2.9.1 Sanpower Corporation Details
2.9.2 Sanpower Corporation Major Business
2.9.3 Sanpower Corporation Dendritic Cell Cancer Vaccines Product and Solutions
2.9.4 Sanpower Corporation Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Sanpower Corporation Recent Developments and Future Plans
2.10 Elios Therapeutics
2.10.1 Elios Therapeutics Details
2.10.2 Elios Therapeutics Major Business
2.10.3 Elios Therapeutics Dendritic Cell Cancer Vaccines Product and Solutions
2.10.4 Elios Therapeutics Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Elios Therapeutics Recent Developments and Future Plans
2.11 ImmunoCellular Therapeutics
2.11.1 ImmunoCellular Therapeutics Details
2.11.2 ImmunoCellular Therapeutics Major Business
2.11.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccines Product and Solutions
2.11.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 ImmunoCellular Therapeutics Recent Developments and Future Plans
2.12 Immunicum
2.12.1 Immunicum Details
2.12.2 Immunicum Major Business
2.12.3 Immunicum Dendritic Cell Cancer Vaccines Product and Solutions
2.12.4 Immunicum Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Immunicum Recent Developments and Future Plans
2.13 Kiromic
2.13.1 Kiromic Details
2.13.2 Kiromic Major Business
2.13.3 Kiromic Dendritic Cell Cancer Vaccines Product and Solutions
2.13.4 Kiromic Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Kiromic Recent Developments and Future Plans
2.14 Medigene
2.14.1 Medigene Details
2.14.2 Medigene Major Business
2.14.3 Medigene Dendritic Cell Cancer Vaccines Product and Solutions
2.14.4 Medigene Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Medigene Recent Developments and Future Plans
2.15 Merck
2.15.1 Merck Details
2.15.2 Merck Major Business
2.15.3 Merck Dendritic Cell Cancer Vaccines Product and Solutions
2.15.4 Merck Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Merck Recent Developments and Future Plans
2.16 Northwest Biotherapeutics
2.16.1 Northwest Biotherapeutics Details
2.16.2 Northwest Biotherapeutics Major Business
2.16.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccines Product and Solutions
2.16.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Northwest Biotherapeutics Recent Developments and Future Plans
2.17 Glaxo Smith Kline
2.17.1 Glaxo Smith Kline Details
2.17.2 Glaxo Smith Kline Major Business
2.17.3 Glaxo Smith Kline Dendritic Cell Cancer Vaccines Product and Solutions
2.17.4 Glaxo Smith Kline Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Glaxo Smith Kline Recent Developments and Future Plans
2.18 Tellaorporation
2.18.1 Tellaorporation Details
2.18.2 Tellaorporation Major Business
2.18.3 Tellaorporation Dendritic Cell Cancer Vaccines Product and Solutions
2.18.4 Tellaorporation Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 Tellaorporation Recent Developments and Future Plans
2.19 Vaxil BioTherapeutics
2.19.1 Vaxil BioTherapeutics Details
2.19.2 Vaxil BioTherapeutics Major Business
2.19.3 Vaxil BioTherapeutics Dendritic Cell Cancer Vaccines Product and Solutions
2.19.4 Vaxil BioTherapeutics Dendritic Cell Cancer Vaccines Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 Vaxil BioTherapeutics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Dendritic Cell Cancer Vaccines Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Dendritic Cell Cancer Vaccines Players Market Share
3.2.2 Top 10 Dendritic Cell Cancer Vaccines Players Market Share
3.2.3 Market Competition Trend
3.3 Dendritic Cell Cancer Vaccines Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Dendritic Cell Cancer Vaccines Revenue and Market Share by Type (2016-2021)
4.2 Global Dendritic Cell Cancer Vaccines Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Dendritic Cell Cancer Vaccines Revenue Market Share by Application (2016-2021)
5.2 Dendritic Cell Cancer Vaccines Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Dendritic Cell Cancer Vaccines Revenue by Type (2016-2026)
6.2 North America Dendritic Cell Cancer Vaccines Revenue by Application (2016-2026)
6.3 North America Dendritic Cell Cancer Vaccines Market Size by Country
6.3.1 North America Dendritic Cell Cancer Vaccines Revenue by Country (2016-2026)
6.3.2 United States Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
6.3.3 Canada Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
6.3.4 Mexico Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Dendritic Cell Cancer Vaccines Revenue by Type (2016-2026)
7.2 Europe Dendritic Cell Cancer Vaccines Revenue by Application (2016-2026)
7.3 Europe Dendritic Cell Cancer Vaccines Market Size by Country
7.3.1 Europe Dendritic Cell Cancer Vaccines Revenue by Country (2016-2026)
7.3.2 Germany Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
7.3.3 France Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
7.3.5 Russia Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
7.3.6 Italy Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Dendritic Cell Cancer Vaccines Revenue by Type (2016-2026)
8.2 Asia-Pacific Dendritic Cell Cancer Vaccines Revenue by Application (2016-2026)
8.3 Asia-Pacific Dendritic Cell Cancer Vaccines Market Size by Region
8.3.1 Asia-Pacific Dendritic Cell Cancer Vaccines Revenue by Region (2016-2026)
8.3.2 China Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
8.3.3 Japan Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
8.3.4 South Korea Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
8.3.5 India Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
8.3.7 Australia Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Dendritic Cell Cancer Vaccines Revenue by Type (2016-2026)
9.2 South America Dendritic Cell Cancer Vaccines Revenue by Application (2016-2026)
9.3 South America Dendritic Cell Cancer Vaccines Market Size by Country
9.3.1 South America Dendritic Cell Cancer Vaccines Revenue by Country (2016-2026)
9.3.2 Brazil Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
9.3.3 Argentina Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Dendritic Cell Cancer Vaccines Revenue by Type (2016-2026)
10.2 Middle East & Africa Dendritic Cell Cancer Vaccines Revenue by Application (2016-2026)
10.3 Middle East & Africa Dendritic Cell Cancer Vaccines Market Size by Country
10.3.1 Middle East & Africa Dendritic Cell Cancer Vaccines Revenue by Country (2016-2026)
10.3.2 Turkey Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
10.3.4 UAE Dendritic Cell Cancer Vaccines Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Dendritic Cell Cancer Vaccines Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Dendritic Cell Cancer Vaccines Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Dendritic Cell Cancer Vaccines Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Dendritic Cell Cancer Vaccines Revenue (USD Million) by Region (2016-2021)
Table 5. Global Dendritic Cell Cancer Vaccines Revenue Market Share by Region (2021-2026)
Table 6. 3M Company Corporate Information, Head Office, and Major Competitors
Table 7. 3M Company Major Business
Table 8. 3M Company Dendritic Cell Cancer Vaccines Product and Solutions
Table 9. 3M Company Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Activarti Corporate Information, Head Office, and Major Competitors
Table 11. Activarti Major Business
Table 12. Activarti Dendritic Cell Cancer Vaccines Product and Solutions
Table 13. Activarti Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Argos Therapeutics Corporate Information, Head Office, and Major Competitors
Table 15. Argos Therapeutics Major Business
Table 16. Argos Therapeutics Dendritic Cell Cancer Vaccines Product and Solutions
Table 17. Argos Therapeutics Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Batavia Bioservices Corporate Information, Head Office, and Major Competitors
Table 19. Batavia Bioservices Major Business
Table 20. Batavia Bioservices Dendritic Cell Cancer Vaccines Product and Solutions
Table 21. Batavia Bioservices Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Bellicum Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 23. Bellicum Pharmaceuticals Major Business
Table 24. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccines Product and Solutions
Table 25. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Creagene Corporate Information, Head Office, and Major Competitors
Table 27. Creagene Major Business
Table 28. Creagene Dendritic Cell Cancer Vaccines Product and Solutions
Table 29. Creagene Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. DanDrit Biotech Corporate Information, Head Office, and Major Competitors
Table 31. DanDrit Biotech Major Business
Table 32. DanDrit Biotech Dendritic Cell Cancer Vaccines Product and Solutions
Table 33. DanDrit Biotech Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. DCPrime Corporate Information, Head Office, and Major Competitors
Table 35. DCPrime Major Business
Table 36. DCPrime Dendritic Cell Cancer Vaccines Product and Solutions
Table 37. DCPrime Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Sanpower Corporation Corporate Information, Head Office, and Major Competitors
Table 39. Sanpower Corporation Major Business
Table 40. Sanpower Corporation Dendritic Cell Cancer Vaccines Product and Solutions
Table 41. Sanpower Corporation Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Elios Therapeutics Corporate Information, Head Office, and Major Competitors
Table 43. Elios Therapeutics Major Business
Table 44. Elios Therapeutics Dendritic Cell Cancer Vaccines Product and Solutions
Table 45. Elios Therapeutics Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. ImmunoCellular Therapeutics Corporate Information, Head Office, and Major Competitors
Table 47. ImmunoCellular Therapeutics Major Business
Table 48. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccines Product and Solutions
Table 49. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Immunicum Corporate Information, Head Office, and Major Competitors
Table 51. Immunicum Major Business
Table 52. Immunicum Dendritic Cell Cancer Vaccines Product and Solutions
Table 53. Immunicum Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Kiromic Corporate Information, Head Office, and Major Competitors
Table 55. Kiromic Major Business
Table 56. Kiromic Dendritic Cell Cancer Vaccines Product and Solutions
Table 57. Kiromic Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Medigene Corporate Information, Head Office, and Major Competitors
Table 59. Medigene Major Business
Table 60. Medigene Dendritic Cell Cancer Vaccines Product and Solutions
Table 61. Medigene Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Merck Corporate Information, Head Office, and Major Competitors
Table 63. Merck Major Business
Table 64. Merck Dendritic Cell Cancer Vaccines Product and Solutions
Table 65. Merck Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Northwest Biotherapeutics Corporate Information, Head Office, and Major Competitors
Table 67. Northwest Biotherapeutics Major Business
Table 68. Northwest Biotherapeutics Dendritic Cell Cancer Vaccines Product and Solutions
Table 69. Northwest Biotherapeutics Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Glaxo Smith Kline Corporate Information, Head Office, and Major Competitors
Table 71. Glaxo Smith Kline Major Business
Table 72. Glaxo Smith Kline Dendritic Cell Cancer Vaccines Product and Solutions
Table 73. Glaxo Smith Kline Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Tellaorporation Corporate Information, Head Office, and Major Competitors
Table 75. Tellaorporation Major Business
Table 76. Tellaorporation Dendritic Cell Cancer Vaccines Product and Solutions
Table 77. Tellaorporation Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. Vaxil BioTherapeutics Corporate Information, Head Office, and Major Competitors
Table 79. Vaxil BioTherapeutics Major Business
Table 80. Vaxil BioTherapeutics Dendritic Cell Cancer Vaccines Product and Solutions
Table 81. Vaxil BioTherapeutics Dendritic Cell Cancer Vaccines Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. Global Dendritic Cell Cancer Vaccines Revenue (USD Million) by Players (2019-2021)
Table 83. Global Dendritic Cell Cancer Vaccines Revenue Share by Players (2019-2021)
Table 84. Breakdown of Dendritic Cell Cancer Vaccines by Company Type (Tier 1, Tier 2 and Tier 3)
Table 85. Dendritic Cell Cancer Vaccines Players Head Office, Products and Services Provided
Table 86. Dendritic Cell Cancer Vaccines Mergers & Acquisitions in the Past Five Years
Table 87. Dendritic Cell Cancer Vaccines New Entrants and Expansion Plans
Table 88. Global Dendritic Cell Cancer Vaccines Revenue (USD Million) by Type (2016-2021)
Table 89. Global Dendritic Cell Cancer Vaccines Revenue Share by Type (2016-2021)
Table 90. Global Dendritic Cell Cancer Vaccines Revenue Forecast by Type (2021-2026)
Table 91. Global Dendritic Cell Cancer Vaccines Revenue by Application (2016-2021)
Table 92. Global Dendritic Cell Cancer Vaccines Revenue Forecast by Application (2021-2026)
Table 93. North America Dendritic Cell Cancer Vaccines Revenue by Type (2016-2021) & (USD Million)
Table 94. North America Dendritic Cell Cancer Vaccines Revenue by Type (2021-2026) & (USD Million)
Table 95. North America Dendritic Cell Cancer Vaccines Revenue by Application (2016-2021) & (USD Million)
Table 96. North America Dendritic Cell Cancer Vaccines Revenue by Application (2021-2026) & (USD Million)
Table 97. North America Dendritic Cell Cancer Vaccines Revenue by Country (2016-2021) & (USD Million)
Table 98. North America Dendritic Cell Cancer Vaccines Revenue by Country (2021-2026) & (USD Million)
Table 99. Europe Dendritic Cell Cancer Vaccines Revenue by Type (2016-2021) & (USD Million)
Table 100. Europe Dendritic Cell Cancer Vaccines Revenue by Type (2021-2026) & (USD Million)
Table 101. Europe Dendritic Cell Cancer Vaccines Revenue by Application (2016-2021) & (USD Million)
Table 102. Europe Dendritic Cell Cancer Vaccines Revenue by Application (2021-2026) & (USD Million)
Table 103. Europe Dendritic Cell Cancer Vaccines Revenue by Country (2016-2021) & (USD Million)
Table 104. Europe Dendritic Cell Cancer Vaccines Revenue by Country (2021-2026) & (USD Million)
Table 105. Asia-Pacific Dendritic Cell Cancer Vaccines Revenue by Type (2016-2021) & (USD Million)
Table 106. Asia-Pacific Dendritic Cell Cancer Vaccines Revenue by Type (2021-2026) & (USD Million)
Table 107. Asia-Pacific Dendritic Cell Cancer Vaccines Revenue by Application (2016-2021) & (USD Million)
Table 108. Asia-Pacific Dendritic Cell Cancer Vaccines Revenue by Application (2021-2026) & (USD Million)
Table 109. Asia-Pacific Dendritic Cell Cancer Vaccines Revenue by Region (2016-2021) & (USD Million)
Table 110. Asia-Pacific Dendritic Cell Cancer Vaccines Revenue by Region (2021-2026) & (USD Million)
Table 111. South America Dendritic Cell Cancer Vaccines Revenue by Type (2016-2021) & (USD Million)
Table 112. South America Dendritic Cell Cancer Vaccines Revenue by Type (2021-2026) & (USD Million)
Table 113. South America Dendritic Cell Cancer Vaccines Revenue by Application (2016-2021) & (USD Million)
Table 114. South America Dendritic Cell Cancer Vaccines Revenue by Application (2021-2026) & (USD Million)
Table 115. South America Dendritic Cell Cancer Vaccines Revenue by Country (2016-2021) & (USD Million)
Table 116. South America Dendritic Cell Cancer Vaccines Revenue by Country (2021-2026) & (USD Million)
Table 117. Middle East & Africa Dendritic Cell Cancer Vaccines Revenue by Type (2016-2021) & (USD Million)
Table 118. Middle East & Africa Dendritic Cell Cancer Vaccines Revenue by Type (2021-2026) & (USD Million)
Table 119. Middle East & Africa Dendritic Cell Cancer Vaccines Revenue by Application (2016-2021) & (USD Million)
Table 120. Middle East & Africa Dendritic Cell Cancer Vaccines Revenue by Application (2021-2026) & (USD Million)
Table 121. Middle East & Africa Dendritic Cell Cancer Vaccines Revenue by Country (2016-2021) & (USD Million)
Table 122. Middle East & Africa Dendritic Cell Cancer Vaccines Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Dendritic Cell Cancer Vaccines Picture
Figure 2. Global Dendritic Cell Cancer Vaccines Revenue Market Share by Type in 2020
Figure 3. CreaVax
Figure 4. Sipuleucel-T (Provenge)
Figure 5. Others
Figure 6. Dendritic Cell Cancer Vaccines Revenue Market Share by Application in 2020
Figure 7. Pediatrics Picture
Figure 8. Adults Picture
Figure 9. Global Dendritic Cell Cancer Vaccines Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Dendritic Cell Cancer Vaccines Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Dendritic Cell Cancer Vaccines Revenue Market Share by Region (2016-2026)
Figure 12. Global Dendritic Cell Cancer Vaccines Revenue Market Share by Region in 2020
Figure 13. North America Dendritic Cell Cancer Vaccines Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Dendritic Cell Cancer Vaccines Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Dendritic Cell Cancer Vaccines Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Dendritic Cell Cancer Vaccines Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Dendritic Cell Cancer Vaccines Market Drivers
Figure 18. Dendritic Cell Cancer Vaccines Market Restraints
Figure 19. Dendritic Cell Cancer Vaccines Market Trends
Figure 20. 3M Company Recent Developments and Future Plans
Figure 21. Activarti Recent Developments and Future Plans
Figure 22. Argos Therapeutics Recent Developments and Future Plans
Figure 23. Batavia Bioservices Recent Developments and Future Plans
Figure 24. Bellicum Pharmaceuticals Recent Developments and Future Plans
Figure 25. Creagene Recent Developments and Future Plans
Figure 26. DanDrit Biotech Recent Developments and Future Plans
Figure 27. DCPrime Recent Developments and Future Plans
Figure 28. Sanpower Corporation Recent Developments and Future Plans
Figure 29. Elios Therapeutics Recent Developments and Future Plans
Figure 30. ImmunoCellular Therapeutics Recent Developments and Future Plans
Figure 31. Immunicum Recent Developments and Future Plans
Figure 32. Kiromic Recent Developments and Future Plans
Figure 33. Medigene Recent Developments and Future Plans
Figure 34. Merck Recent Developments and Future Plans
Figure 35. Northwest Biotherapeutics Recent Developments and Future Plans
Figure 36. Glaxo Smith Kline Recent Developments and Future Plans
Figure 37. Tellaorporation Recent Developments and Future Plans
Figure 38. Vaxil BioTherapeutics Recent Developments and Future Plans
Figure 40. Global Dendritic Cell Cancer Vaccines Revenue Share by Players in 2020
Figure 41. Dendritic Cell Cancer Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 42. Global Top 3 Players Dendritic Cell Cancer Vaccines Revenue Market Share in 2020
Figure 43. Global Top 10 Players Dendritic Cell Cancer Vaccines Revenue Market Share in 2020
Figure 44. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 45. Global Dendritic Cell Cancer Vaccines Revenue Share by Type in 2020
Figure 46. Global Dendritic Cell Cancer Vaccines Market Share Forecast by Type (2021-2026)
Figure 47. Global Dendritic Cell Cancer Vaccines Revenue Share by Application in 2020
Figure 48. Global Dendritic Cell Cancer Vaccines Market Share Forecast by Application (2021-2026)
Figure 49. North America Dendritic Cell Cancer Vaccines Sales Market Share by Type (2016-2026)
Figure 50. North America Dendritic Cell Cancer Vaccines Sales Market Share by Application (2016-2026)
Figure 51. North America Dendritic Cell Cancer Vaccines Revenue Market Share by Country (2016-2026)
Figure 52. United States Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Canada Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Mexico Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Europe Dendritic Cell Cancer Vaccines Sales Market Share by Type (2016-2026)
Figure 56. Europe Dendritic Cell Cancer Vaccines Sales Market Share by Application (2016-2026)
Figure 57. Europe Dendritic Cell Cancer Vaccines Revenue Market Share by Country (2016-2026)
Figure 58. Germany Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. France Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. United Kingdom Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Russia Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Italy Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Asia-Pacific Dendritic Cell Cancer Vaccines Sales Market Share by Type (2016-2026)
Figure 64. Asia-Pacific Dendritic Cell Cancer Vaccines Sales Market Share by Application (2016-2026)
Figure 65. Asia-Pacific Dendritic Cell Cancer Vaccines Revenue Market Share by Region (2016-2026)
Figure 66. China Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Japan Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. South Korea Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. India Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Southeast Asia Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Australia Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. South America Dendritic Cell Cancer Vaccines Sales Market Share by Type (2016-2026)
Figure 73. South America Dendritic Cell Cancer Vaccines Sales Market Share by Application (2016-2026)
Figure 74. South America Dendritic Cell Cancer Vaccines Revenue Market Share by Country (2016-2026)
Figure 75. Brazil Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Argentina Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Middle East and Africa Dendritic Cell Cancer Vaccines Sales Market Share by Type (2016-2026)
Figure 78. Middle East and Africa Dendritic Cell Cancer Vaccines Sales Market Share by Application (2016-2026)
Figure 79. Middle East and Africa Dendritic Cell Cancer Vaccines Revenue Market Share by Country (2016-2026)
Figure 80. Turkey Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Saudi Arabia Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 82. UAE Dendritic Cell Cancer Vaccines Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 83. Methodology
Figure 84. Research Process and Data Source
世界のmRNAがんワクチン・治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global mRNA Cancer Vaccines and Therapeutics Market The global mRNA Cancer Vaccines and Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and…- 世界のがんワクチン薬剤用パイプライン市場規模・現状・予測（2021年-2027年） Cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. Germany, the U.S. and Japan represent the largest markets for cancer vaccine manufacturers. Market Analysis and Insights: Global Cancer Vaccines Drug Pipeline Mark…
- 世界のがん幹細胞（CSC）治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Cancer Stem Cell Therapy Market The global Cancer Stem Cell Therapy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the …
- 世界の基底細胞皮膚がん治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Basal Cell Skin Cancer Treatment Market The global Basal Cell Skin Cancer Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data…
- 世界の基底細胞皮膚がん治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Basal Cell Skin Cancer Treatment Market The global Basal Cell Skin Cancer Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data…